Evidence map›Paper›PMID 40822943›Full record

ArticleFrontiers in endocrinology2025

Understanding obesity in children with 22q11.2 deletion syndrome.

Walter Maria Sarli, Matteo Cerutti, Matteo Pontone, Valentina Guarnieri, Sara Soldovieri, Massimo Giotta, Silvia Ricci, Chiara Azzari, Stefano Stagi

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Walter Maria Sarli *Immunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Matteo Cerutti *Department of Health Sciences, University of Florence, Florence, Italy.
Matteo Pontone *Department of Health Sciences, University of Florence, Florence, Italy.
Valentina GuarnieriImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Sara SoldovieriDepartment of Health Sciences, University of Florence, Florence, Italy.
Massimo GiottaPhD School in Public Health, Clinical Medicine and Oncology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy.
Silvia RicciImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Chiara AzzariImmunology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Stefano StagiDepartment of Health Sciences, University of Florence, Florence, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: 22q11.2 deletion syndrome (22q11.2DS) is a complex and heterogeneous genetic disorder. While short stature is well-documented, data on weight excess in pediatric patients remain sparse and conflicting. Objective: To evaluate the prevalence of overweight and obesity in children and adolescents with 22q11.2DS when compared to the general Italian pediatric population and identify risk factors and periods of critical weight gain. Methods: In this single-center, retrospective study, 61 children with molecularly confirmed 22q11.2DS were followed up for 441 patient-years. Anthropometric data were evaluated and compared to national surveillance databases ("OKKio alla Salute" and "HBSC"). Risk factors for overweight and obesity were identified by univariate and multivariate analyses. Results: While overweight prevalence in 22q11.2DS patients did not differ significantly from that in the general population, obesity had a bimodal age distribution with peaks at 11 and 17 years. Both neuropsychiatric comorbidities and the use of psychoactive medication were significantly associated with an increased risk of overweight and obesity. In multivariate analysis, the use of psychoactive medication was the only independent risk factor. Conclusions: Obesity in 22q11.2DS may not be syndrome-intrinsic but is heavily influenced by pharmacological treatment. Identification of vulnerable periods and modifiable risk factors is crucial. A preventive, multidisciplinary approach with metabolic screening and cautious use of psychotropic medication is warranted to avoid obesity risk in this population.

Indexed as

DiGeorge SyndromePediatric ObesityAdolescentBody Mass IndexChildChild, PreschoolFemaleFollow-Up StudiesHumansItalyMaleOverweightPrevalenceRetrospective StudiesRisk Factors22q11 deletion syndromechildrenDiGeorgeneuropsychiatric diseaseobesityoverweightpreventionthyroid

Identifiers

PMID40822943
PMCPMC12350139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.